Navigation Links
New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
Date:12/18/2007

x in patients with inhalational anthrax disease in the event of an emergency prior to FDA licensure.

About Anthrax

Anthrax infection is caused by a spore-forming bacterium, Bacillus anthracis, which multiplies in the body and produces lethal toxins. Most anthrax fatalities are caused by the irreversible effects of the anthrax toxins. Research has shown that the bacteria produce protective antigen, the key facilitator in the progression of anthrax infection at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. ABthrax blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing. ABthrax (raxibacumab) is in late- stage development for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. For more information about ABthrax, please visit http://www.hgsi.com/products/ABthrax.html. Health professionals or patients
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Mindful Approach to Aging
2. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
3. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
4. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
7. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
8. Promising Results in Treating Facial Bruising From Injectables
9. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
10. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
11. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... June 20, Actelion Ltd (SWX: ATLN) announced today ... mildly symptomatic pulmonary,arterial hypertension (PAH) patients (WHO functional ... clinical deterioration by significantly,delaying time to clinical worsening ... FC III/IV. A significant reduction in pulmonary vascular,resistance ...
... PXS; Nasdaq: PXSL) today announced that the company ... reached agreement on the phase 3,registration trial of ... The SPA process allows for FDA evaluation ... primary basis of an efficacy claim in support ...
Cached Medicine Technology:Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 2Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 3Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 4Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 5Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 6Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3
(Date:8/20/2014)... Research has been chosen by Plymouth University to be ... in April 2009 to raise awareness of, and funding ... for brain tumour patients. , A range of events ... for the charity, and members of staff and students, ... to donate, fundraise and volunteer. The involvement of the ...
(Date:8/20/2014)... Boston, MA (PRWEB) August 20, 2014 Fresh ... new jogging stroller just sprung from the starting blocks. , ... design studios, has added the Urbini Avi jogger ... for nearly a year, with a look inspired by the ... and delight fitness-minded parents. , This versatile jogger offers a ...
(Date:8/20/2014)... 20, 2014 Parents and kids across ... from summer months means buying textbooks and arranging after ... often a forgotten part of the annual re-commitment to ... the American Psychological Association, 27% of students say they ... (45%) say they are stressed by school pressures. The ...
(Date:8/20/2014)... 20, 2014 The report “Automotive ... - A Global Analysis: by Geography - Trends ... classifies and defines automotive airbag and seatbelt market ... highlights potential growth opportunities in the coming years ... market drivers, restrains, growth indicators, challenges, legislation trends, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Shepherd Health Care System in Hermiston, Ore. The top ... B. E. Smith has recently placed more than 900 ... Care System is a progressive, not-for-profit healthcare organization serving ...
Breaking Medicine News(10 mins):Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3
... doctors in hospital and general practice are being concerned about a ... that 93% of those with worries had taken some form of ... 10% of GPs and 4% of hospital doctors had taken no ... expressed concerns and even made reference to possible alcohol abuse. ...
... Calcutta Medical College and Hospital expressed their support to ... northern region of the State. West Bengal is ... ,Barring the emergency department, services in the Calcutta ... doctors and interns struck work against the central government's ...
... Dr. Michael Thun of the American Cancer Society it was found ... wee less.// On the other hand men who never smoked had ... among a million Americans. Lung cancer is by far the biggest ... this year in the United States alone. ,This report ...
... moderate exercise regimen for 30-45 minutes, performed on all weekdays ... cancer in women. Breast cancer// is the most common form ... women at some stage of their life in the Western ... achieve early detection and effective treatment, about 20 percent of ...
... scare not yet ascertained the top floors of the Melbourne ... to identify the cause of illnesses.// ,Tests on ... to establish any link as yet to the seven cases ... ,Five of these seven cases were employees who had ...
... to researchers at the University of Pennsylvania and Temple ... important role in diseases of the eye. This is ... covering the eyes.// The researchers, led by Mina ... Institute, and Marcella Macaluso, Ph.D., of the Sbarro Institute ...
Cached Medicine News:Health News:Increase In The Number Of Doctors Reporting About Their Colleagues Abilities 2Health News:Medicos Of The Calcutta Medical College Join Anti-Reservation Quota Protest 2Health News:Moderate Exercise, Key To Breast Cancer Prevention 2Health News:PAI-2 Plays a Pivotal Role in Eye Infections 2
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
Diamond phaco knife keratome shaped blade straight. 3.2 mm wide....
... Excaliburplus PC, 100V, 50Hz/60Hz is the most ... V PTP in spray Coag. It is the ... power settings from the surgical field with a ... Output Voltage in CUT maintains minimum necessary voltage ...
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Medicine Products: